GLP-1 Specialist · One Named Clinician · Hampstead NW3

Specialist Medical Weight Management in Hampstead, NW3.

The same Independent Prescriber at every visit, whether in person at our Hampstead clinic or by secure video.

Mahyar Saremi has practised as a Specialist Prescribing Pharmacist for over a decade, with dedicated obesity-medicine training through the World Obesity Federation’s SCOPE programme.

  • From £149 a month
  • Weekly Injections or Daily Tablets
  • Same Prescriber Every Visit
  • Face-to-Face or Video
  • Walk Out With Your Medication
  • GP & Specialist Liaison
  • £30 booking deposit, deducted from your treatment cost
  • No subscription, no fixed contract
  • GP and specialist liaison, with your consent
35 South End Road, NW3 2PY Opposite Hampstead Heath Rail Station GPhC Registered Premises 1040582
Mahyar Saremi, Specialist Prescribing Pharmacist and Independent Prescriber, at the Hampstead Heath Pharmacy consulting room
Mahyar Saremi, Independent Prescriber · GPhC 2069409

Programme & Pricing

Transparent pricing. No subscription.

Every cost named, every line itemised. Pay only for what you use, when you use it. No fixed contracts, no auto-renewing monthly fees, no hidden ‘administration’ charges.

How our pricing works

  • £30 booking deposit at the time of booking. Fully deducted from the cost of your treatment when you visit, provided you adhere to our cancellation policy.
  • No subscription, no fixed contract. You pay per pen or per tablet pack as you collect or receive your medication, nothing more and nothing on autopilot.
  • Stop or pause at any time with no cancellation penalty. We’ll discuss the clinical considerations of stopping, but the choice remains yours.

What’s included with your medication

  • Initial consultation with Mahyar (in person or by video)
  • Eligibility, history and medication review
  • Individual dose escalation plan
  • Side-effect support throughout treatment
  • Dedicated WhatsApp channel for between-visit questions
  • Follow-up consultations (no separate consultation fee)
  • GP and specialist liaison letters
  • MHRA Yellow Card pharmacovigilance

Per pen · 4 weeks of treatment

Mounjaro®

tirzepatide · Eli Lilly

Strength Price per pen
2.5 mg£195
5 mg£210
7.5 mg£260
10 mg£285
12.5 mg£303
15 mg£323

2.5 mg is the starting dose for the first 4 weeks. Dose is escalated only when clinically appropriate and tolerated.

Per pen · 4 weeks of treatment

Wegovy®

semaglutide · Novo Nordisk

Strength Price per pen
0.25 mg£149
0.5 mg£149
1 mg£149
1.7 mg£199
2.4 mg£249
7.2 mg£253

Standard escalation runs across the lower strengths over the first months before reaching the maintenance dose.

Wegovy® Oral

semaglutide tablets · Novo Nordisk · once-daily tablet

Per pack · 30 tablets, about one month

Strength Price
1.5 mg£158
4 mg£160
9 mg£175
25 mg£220
  • One tablet, once a day, taken by mouth rather than injected.
  • No needles and no sharps bin required.
  • Kept at room temperature in its blister, so no fridge or cold-chain delivery is needed.
  • The same active medicine (semaglutide) as the Wegovy pen.

Licensed in the UK by the MHRA on 11 June 2026. The dose is built up gradually, about a month at each strength, and the right dose for you is agreed with Mahyar. The 25 mg tablet is broadly equivalent to the 2.4 mg injection. You can book a consultation to start or switch, with your medication supplied by collection or by post.

New

Foundayo®

orforglipron · Eli Lilly · once-daily tablet

Per pack · 30 tablets, about one month

Strength Price
0.8 mg£149
2.5 mg£149
5.5 mg£149
9 mg£168
14.5 mg£196
17.2 mg£196
  • One tablet, once a day, at any time of day, with no food or water restrictions.
  • No needles and no sharps bin required.
  • Kept at room temperature, so no fridge or cold-chain delivery is needed.
  • The same price for the first three strengths, so your monthly cost stays the same while your dose is built up.

Licensed in the UK by the MHRA on 10 August 2026, the first authorisation of this GLP-1 tablet in Europe. Foundayo contains orforglipron, a different active medicine from Wegovy (semaglutide) and Mounjaro (tirzepatide), with its own dose ladder, so milligram strengths are not comparable between products. The dose is built up gradually, at least a month at each strength, and the right dose for you is agreed with Mahyar. You can book a consultation to start or switch, with your medication supplied by collection or by post.

Add-ons

Our usual dispatch days are Monday and Thursday. Order by 1pm on a dispatch day and your medication is posted that afternoon by Royal Mail Special Delivery, Guaranteed by 1pm the next day, so it spends under 24 hours in transit. Pen orders ship in insulated packaging with ice packs to hold the cold chain for the journey, with no separate cold-chain handling fee. Tablet packs travel safely at room temperature.

  • Delivery for 1 or 2 pens Standard delivery for one or two pens together. £12
  • Delivery for 3 pens, or first pen delivery For three pens together, or your first pen delivery package (1 pen plus pen needles plus sharps bin). £16
  • Delivery for tablet packs Up to three tablet packs together, shipped at room temperature. £12
  • Pen needles Box of 100 compatible 4 mm single-use pen needles. £5
  • Sharps disposal bin Small clinical-waste bin for safe disposal of used needles. £2
Cancellation & refunds. Your £30 deposit is deducted from the cost of treatment if you attend your appointment, including if you’re assessed as not suitable for treatment. We ask that you give reasonable notice if you need to cancel or reschedule. Prices are subject to change, and the prices charged at your appointment will be the prices displayed in the clinic on that day.

Why a specialist matters

Three credentials behind every consultation.

Weight-management medicines are powerful and require careful dose decisions, side-effect management, and ongoing review. Here are the qualifications and experience your prescriber brings to that work.

SCOPE · World Obesity Federation

Trained in Obesity Medicine

Mahyar has completed the SCOPE Core Learning Path, a formal obesity-medicine programme run by the World Obesity Federation. It covers eligibility assessment, comorbidity management, behavioural support, and the safe clinical use of weight-management medicines.

For you

Your suitability, side-effect management, and lifestyle support are assessed against a structured obesity-medicine framework — not by an algorithm or a generic intake form.

NHS Borough & Formulary Lead

Senior NHS Prescribing Advisor

Until May 2024, Mahyar was Borough Lead Pharmacist for the NHS North West London ICB Medicines Optimisation Team and Lead Formulary Pharmacist for the North West London Integrated Formulary — a population of around 2.4 million. The role required formal judgments about which medicines were safe and clinically appropriate to prescribe, including in patients with co-morbidities and complex polypharmacy.

For you

If you take other medicines or have complex health conditions, you’re consulting with a prescriber whose career has centred on assessing exactly these situations safely.

IPresc · Since 2012

Independent Prescriber for Over a Decade

Mahyar has held independent prescribing rights since 2012. That covers the entire period in which licensed weight-management treatments have been introduced to the UK private market — over a decade of continuous, hands-on prescribing experience in this area.

For you

Your care isn’t dictated by a rigid protocol. Mahyar can prescribe supportive treatment for common side effects — nausea, reflux, constipation — in the same consultation, and adapt your plan as your needs change.

Verifiable. GPhC pharmacist registration 2069409. GPhC registered premises 1040582. Faculty of Travel Medicine, Royal College of Physicians and Surgeons of Glasgow — full member.

Why Supervision Matters

A review with every supply.

The medicine matters less than how it is managed. Doses change, side effects move, and decisions need an experienced clinician, so we built the reviews into the way we supply.

Four to five dose decisions in your first six months

UK schedules build the dose up in steps, roughly monthly at first. Whether you are on the weekly injection or the daily tablet, your first six months typically include four to five separate decisions about moving up, holding, or stepping back. Each one deserves a proper review, not an automatic reorder.

Side effects cluster around dose changes

The trial charts further down this page show it clearly: nausea and other effects peak in the weeks after each escalation, then settle. Being reviewed at every change means doses are adjusted early, before a manageable side effect becomes a reason to give up.

One month at a time while your dose is changing

We do not bulk-ship months of medication to a new patient against an online questionnaire. While your dose is changing, you receive one month of medicine at a time, with a review of your dose, side effects, weight trend and other medicines at every supply, from the same prescriber. Once you are stable on your maintenance dose, we can supply more than one month at a time where that suits you and is clinically appropriate.

Verified in person, not self-declared

UK pharmacy regulators now expect height and weight to be independently verified before these medicines are supplied remotely, rather than taken on trust from an online form. We verify yours on calibrated scales with photo ID, in person or by video, before anything is prescribed.

Over 600 patients seen at our Hampstead clinic Same named prescriber at every visit Follow-up reviews included, no consultation fees
Book Your Consultation

A £30 deposit reserves your appointment and is deducted from your treatment cost.

Your clinical team

One prescriber, one team. Built for continuity.

You’ll be cared for by a small, named team — not assigned to whoever happens to be on shift. The same prescriber leads every consultation, supported by clinic colleagues who know your programme.

Mahyar Saremi, Superintendent Pharmacist and Specialist Independent Prescriber at Hampstead Heath Pharmacy
Mahyar Saremi Superintendent Pharmacist & Specialist Independent Prescriber MPharm · PGCert PharmPract · IPresc · MFTM RCPS(Glasg) · CTH

Mahyar is the Superintendent Pharmacist and Specialist Independent Prescriber at Hampstead Heath Pharmacy. He qualified at Liverpool John Moores University, completed his hospital training at Homerton Hospital, and worked as a rotational pharmacist at the Royal Free Hospital before gaining his independent prescribing qualification in 2012.

Until May 2024, Mahyar held senior NHS prescribing roles as Borough Lead Pharmacist for the NHS North West London ICB Medicines Optimisation Team and Lead Formulary Pharmacist for the North West London Integrated Formulary — serving a population of around 2.4 million. The work centred on assessing the safety and clinical appropriateness of medicines for patients with co-morbidities and complex polypharmacy. That same judgment now informs every weight-management consultation.

Mahyar has prescribed across every generation of licensed weight-management medicine introduced to the UK private market, with continuous clinical experience over more than seven years. He has completed dedicated obesity-medicine training through the World Obesity Federation’s SCOPE programme, and now leads the weight-management clinic at Hampstead Heath Pharmacy — supported by the wider team below.

Already on treatment elsewhere?

Switch without starting over.

Many of our patients transfer from online providers because of real frustrations: rotating prescribers, supply delays, rigid restart protocols that erase your progress, no meaningful monitoring of how treatment is working, and unmanaged side effects that can compromise safety. If that’s you, here’s what changes when you switch to us.

Your dose continues, where it’s safe to.

If you’re stable on a working dose and tolerating it well, we will not automatically restart you at the starting dose. Mahyar continues from your current dose, or one step down where indicated for safety.

The same prescriber at every visit.

Mahyar makes every clinical decision in your treatment — assessment, dose changes, side-effect support. No rotating prescribers, no different name on each renewal.

We monitor what matters.

Body-composition changes, side-effect patterns, dose tolerability, and clinical response are reviewed at every appointment — not just whether you’re due a refill. Consistent oversight catches issues early, including muscle loss, which is a known concern with these medicines.

Reliable supply from a real pharmacy.

All strengths held in stock at our Hampstead premises. Walk out with your medication on the day, or have it delivered with insulated packaging and ice packs by Royal Mail Special Delivery.

How switching works

  1. Book a FIRST Appointment — in person at our Hampstead clinic, or by secure video.
  2. Complete the intake questionnaire (emailed to you immediately after booking) and upload evidence of your most recent supply from your current provider — e.g. a prescription label or dispensing receipt.
  3. Attend your consultation. Mahyar reviews your prescribing history, current dose, and side-effect record, and prescribes from a clinically appropriate dose.
Book your switching consultation

£30 deposit, deducted from treatment cost. No subscription or fixed contract.

Eligibility

Is this service for you?

We’re transparent about who this programme is for, and who it isn’t. Both matter — for your safety, and for an honest first consultation.

Suitable for

Adults whose weight is affecting their health.

  • BMI of 30 kg/m² or above
  • BMI of 27 kg/m² or above with a weight-related health condition — for example raised blood pressure, raised cholesterol, pre-diabetes, or type 2 diabetes.
Calculate your BMI on the NHS website

We particularly welcome patients with:

  • Polycystic ovary syndrome (PCOS)

    Insulin resistance and hormonal patterns make weight loss genuinely harder. Your assessment accounts for this, and your treatment plan is tailored accordingly.

  • Peri- and post-menopausal weight gain

    Hormonal and metabolic changes around menopause are common, real, and often dismissed elsewhere. We don’t dismiss them.

  • Underactive thyroid (hypothyroidism)

    Stable hypothyroidism, including Hashimoto’s, often makes weight loss harder. Some automated services exclude this group on the basis of an overcautious blanket thyroid rule. We don’t.

  • Polypharmacy and multiple long-term conditions

    If you take several medicines or live with several long-term conditions, drug interactions and clinical context matter. Mahyar’s NHS formulary background is built for exactly this kind of assessment.

  • Post-bariatric weight regain

    Weight regain after bariatric surgery is common and clinically distinct from primary weight gain. Your surgical history is factored into every prescribing decision.

Not suitable if you have

Conditions that make these medicines unsafe or inappropriate.

  • A BMI under 27 kg/m² — these medicines aren’t licensed or appropriate for this group.
  • Pregnancy, or planning pregnancy soon — these medicines must be discontinued before conception. We’ll discuss the right washout period during your consultation.
  • Currently using insulin — whether for type 1 or type 2 diabetes. Combining insulin with these medicines significantly raises the risk of hypoglycaemia, which requires closer monitoring than this service provides.
  • Severe gastroparesis — these medicines slow gastric emptying and would be expected to worsen the condition.
  • An active eating disorder — appropriate care for an active eating disorder is best provided by a specialist eating-disorder service.
  • A history of pancreatitis — we assess case by case; this isn’t an automatic exclusion, but it does require careful clinical judgment.
Patient education

About the medicine

Mounjaro® (tirzepatide)

Tirzepatide is a once-weekly injection licensed for weight management in adults. This is general information, not a substitute for the Patient Information Leaflet or a clinical consultation. Whether it suits you, and at what dose, is decided with Mahyar.

Generic name tirzepatide
Brand & manufacturer Mounjaro® · Eli Lilly
Drug class Dual GIP & GLP-1 receptor agonist
Administration Once-weekly subcutaneous injection

How it works

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, where earlier weight-management medicines target GLP-1 alone. The result: less hunger and fewer food cravings, slower gastric emptying so meals satisfy for longer, and better blood-sugar handling, with insulin released only when glucose is high.

Clinical evidence: SURMOUNT-1

The pivotal SURMOUNT-1 trial followed 2,539 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes, on weekly tirzepatide or placebo for 72 weeks, alongside a reduced-calorie diet and more activity.

Mean Weight Change at 72 Weeks (SURMOUNT-1) Bar chart: tirzepatide 5 mg minus 16.0 percent, 10 mg minus 21.4 percent, 15 mg minus 22.5 percent, placebo minus 2.4 percent. Mean Weight Change at 72 Weeks TIRZEPATIDE PLACEBO 0 −5 −10 −15 −20 −25 Percentage Change (%) −16.0 −21.4 −22.5 −2.4 5 mg 10 mg 15 mg Placebo

Trial averages at 72 weeks, alongside diet and activity changes; individual results vary substantially. Figures are the efficacy estimand: the average effect if participants had stayed on treatment for all 72 weeks. At least 5% of body weight was lost by 89.4% (5 mg), 96.2% (10 mg) and 96.3% (15 mg) of participants, against 27.9% on placebo. Source: Mounjaro UK Summary of Product Characteristics, section 5.1 (SURMOUNT-1).

How tirzepatide is prescribed

Treatment starts on 2.5 mg for four weeks, moves to 5 mg, then steps up only as far as you need:

2.5 mg Starting dose
5 mg Maintenance dose
7.5 mg Step-up dose
10 mg Maintenance dose
12.5 mg Step-up dose
15 mg Maximum dose

Each further step waits at least four weeks and depends on your response and tolerability: some patients settle at 5 mg or 10 mg long-term, others continue to 15 mg. Prices are in Programme & Pricing above.

The six Mounjaro KwikPen cartons, tirzepatide solution for injection, from 2.5 mg to 15 mg, each holding one once-weekly pen with four doses.
The six Mounjaro KwikPens. Each holds four weekly doses and is kept in the fridge. Inject on the same day each week; a missed dose can be taken up to four days late, otherwise skip it.

Key safety considerations

Digestive side effects are the most common: nausea, diarrhoea, vomiting, constipation and stomach pain. In the weight-management trials they affected 55.6% to 55.8% of people on tirzepatide, against 29.7% on placebo, and led 1.9% to 4.3% to stop treatment, against 0.5%. They are usually mild to moderate, most frequent while the dose is stepping up, and ease over time.

When to seek immediate medical attention

  • Pancreatitis. Severe pain in the stomach and back that does not go away. Stop tirzepatide and seek immediate medical attention; it must not be restarted if pancreatitis is confirmed.
  • Serious allergic reaction. Breathing problems, rapid swelling of the lips, tongue or throat, or a fast heartbeat. Get immediate medical help.
  • Gallbladder problems. Pain in the upper right of the tummy, fever, or yellowing of the skin or eyes. Seek prompt assessment.

Gallstones affect up to 1 in 10 people, pancreatitis up to 1 in 100 and serious allergic reactions up to 1 in 1,000. We brief every patient on these signs and report serious effects to the MHRA.

Other points to discuss before or during treatment

  • The contraceptive pill. Tirzepatide may make it less effective. Switch to a non-oral method, or add a barrier method such as condoms, for four weeks after starting and for four weeks after every dose increase.
  • Pregnancy and breast-feeding. Not for use in pregnancy: use contraception, and stop at least one month before trying to conceive. If you are breast-feeding, talk to us first.
  • Other medicines. With insulin or a sulfonylurea, blood sugar can fall too low; warfarin and digoxin may need closer monitoring. Bring a full list of everything you take.
  • Staying hydrated. Vomiting or diarrhoea can cause dehydration, which can affect the kidneys. Keep fluids up.
  • Operations. Tell the team beforehand if you are having a general anaesthetic or deep sedation.

Authoritative information & resources

Discuss whether tirzepatide is right for you

A real clinical conversation, not a tick-box form. £30 deposit, deducted from treatment cost.

Patient education

About the medicine

Wegovy® (semaglutide)

Semaglutide comes as the established once-weekly injection and a once-daily tablet. This is general information, not a substitute for the Patient Information Leaflet or a clinical consultation. Which form and dose suit you is decided with Mahyar.

Generic name semaglutide
Brand & manufacturer Wegovy® · Novo Nordisk
Drug class GLP-1 receptor agonist
Administration Weekly injection or daily tablet

How it works

Semaglutide mimics GLP-1, a gut hormone released after eating. The result: less hunger and fewer food cravings, feeling full for longer, and better blood-sugar handling, with insulin released only when glucose is high.

Clinical evidence

In the pivotal STEP 1 trial, people who stayed on weekly 2.4 mg lost a mean 16.9% of their weight over 68 weeks (2.4% on placebo), and about 69% of participants lost at least 10% (12% on placebo). STEP UP then tested 7.2 mg against 2.4 mg and placebo in adults with obesity, all alongside a reduced-calorie diet and more activity.

Mean Weight Change at 72 Weeks (STEP UP) Bar chart, participants who stayed on treatment: Wegovy 7.2 mg minus 20.7 percent, Wegovy 2.4 mg minus 17.5 percent, placebo minus 2.4 percent. Mean Weight Change at 72 Weeks 0 −5 −10 −15 −20 −25 Percentage Change (%) −20.7 −17.5 −2.4 Wegovy 7.2 mg Wegovy 2.4 mg Placebo

STEP UP at 72 weeks, assuming participants stayed on treatment; individual results vary substantially. On 7.2 mg, about one in three lost 25% or more. Counting every participant, the SmPC’s main analysis gives 18.7%, 15.6% and 3.9% for STEP UP and 14.9% for STEP 1. Sources: Wegovy UK Summary of Product Characteristics, section 5.1; Wilding JPH et al, NEJM 2021 for the 69% figure.

How semaglutide is prescribed

The injection starts low and steps up every four weeks to the 2.4 mg maintenance dose:

0.25 mg Starting dose
0.5 mg Step-up
1 mg Step-up
1.7 mg Step-up
2.4 mg Maintenance dose
7.2 mg Higher maintenance dose

If a step doesn’t suit you, we hold or step back until symptoms settle. For adults with obesity, the dose can go on to 7.2 mg if needed, after at least four weeks on 2.4 mg.

Wegovy (semaglutide) dose-escalation schedule. Five multi-dose FlexTouch pens, each holding four weekly doses: 0.25 mg for weeks 1 to 4 as the initiation dose, then stepping up through 0.5 mg (weeks 5 to 8), 1 mg (weeks 9 to 12) and 1.7 mg (weeks 13 to 16) to the 2.4 mg maintenance dose from week 17. A separate 7.2 mg single-dose pre-filled pen, supplied four pens per pack, is taken from week 21 onwards.
Wegovy® dose-escalation schedule. 0.25 to 2.4 mg come as FlexTouch® pens holding four weekly doses; 7.2 mg is a single-dose pen, four per pack. Keep pens in the fridge; a missed dose can be taken up to five days late, otherwise skip it.

Wegovy as a daily tablet (oral semaglutide)

Wegovy also comes as a once-daily tablet, with its own dose ladder and way of being taken. The other tablet we prescribe, Foundayo (orforglipron), is a different medicine.

Wegovy 1.5 mg tablets carton, semaglutide, oral use, 30 tablets. 1.5 mg Starting dose
Wegovy 4 mg tablets carton, semaglutide, oral use, 30 tablets. 4 mg Step 2
Wegovy 9 mg tablets carton, semaglutide, oral use, 30 tablets. 9 mg Step 3
Wegovy 25 mg tablets carton, semaglutide, oral use, 30 tablets. 25 mg Maintenance

Each step lasts at least a month. Tablet and injection milligrams are different scales: the 25 mg tablet corresponds to the 2.4 mg injection, and no tablet matches 7.2 mg.

How the tablet is taken

  1. On an empty stomach, at least 8 hours after eating (for most, first thing in the morning).
  2. Swallow it whole with a sip of water (up to 120 mL). Do not split, crush or chew it.
  3. Wait at least 30 minutes before eating, drinking or taking other oral medicines; less reduces how much is absorbed.
  4. One tablet a day. Miss a dose? Skip it and carry on the next day. Keep tablets in their blister, away from moisture and light.

In its 64-week trial (OASIS 4), people who stayed on the 25 mg tablet lost a mean 16.6% (2.8% on placebo); counting every participant, 13.6% (2.2%), with about 6 in 10 losing at least 10%. A separate trial, so not comparable with the injection figures. Side effects match the injection’s; the safety points below cover both forms.

Ready to start or switch?

A direct switch runs from the 2.4 mg injection to the 25 mg tablet a week after your last injection, or back the day after your last tablet. From a lower dose, Mounjaro or Foundayo, the move is planned individually.

Book a consultation

Key safety considerations

Digestive side effects are the most common. On 2.4 mg, nausea affected 43.9% (16.1% on placebo), diarrhoea 29.7% (15.9%), vomiting 24.5% (6.3%) and constipation 24.2% (11.1%), and 4.3% stopped treatment because of them; rates on 7.2 mg and the tablet were similar. They are usually mild to moderate and ease over time. On 7.2 mg, 21.6% noticed altered skin sensation such as tingling (0.3% on placebo), which usually settles. Every Wegovy form carries the ▼ black triangle, so please report any suspected side effect.

When to seek immediate medical attention

  • Pancreatitis. Severe pain in the stomach and back that does not go away. Stop semaglutide and seek immediate medical attention; it must not be restarted if pancreatitis is confirmed.
  • Sudden vision changes. Sudden loss of vision, even partial, or worsening eyesight. Contact a doctor urgently: it can signal a serious eye condition (NAION).
  • Serious allergic reaction. Breathing problems, swelling of the face, lips, tongue or throat, wheezing or a fast heartbeat. Get immediate medical help.
  • Bowel obstruction. Severe constipation with stomach ache, bloating or vomiting.
  • Gallbladder problems. Pain in the upper right of the tummy, fever, or yellowing of the skin or eyes. Seek prompt assessment.

Gallstones affect up to 1 in 10 people, pancreatitis up to 1 in 100, serious allergic reactions up to 1 in 1,000 and NAION up to 1 in 10,000. We brief every patient on these signs and report serious effects to the MHRA.

Other points to discuss before or during treatment

  • Pregnancy and breast-feeding. Not for use in either. Use contraception, and stop at least two months before trying to conceive.
  • Diabetes. Insulin or sulfonylurea doses may need reducing to avoid low blood sugar, and diabetic eye disease needs monitoring.
  • Other medicines. Warfarin needs closer monitoring when you start. With the tablet, levothyroxine may need thyroid checks.
  • Staying hydrated. Vomiting or diarrhoea can cause dehydration, which can affect the kidneys. Keep fluids up.
  • Operations. Tell the team beforehand if you are having a general anaesthetic or deep sedation.

Authoritative information & resources

Discuss whether semaglutide is right for you

A real clinical conversation, not a tick-box form. £30 deposit, deducted from treatment cost.

Patient education

About the medicine

Wegovy® (semaglutide)

Semaglutide comes as the established once-weekly injection and a once-daily tablet. This is general information, not a substitute for the Patient Information Leaflet or a clinical consultation. Which form and dose suit you is decided with Mahyar.

Generic name semaglutide
Brand & manufacturer Wegovy® · Novo Nordisk
Drug class GLP-1 receptor agonist
Administration Weekly injection or daily tablet

How it works

Semaglutide mimics GLP-1, a gut hormone released after eating, and is one of the most extensively studied weight-management medicines. The result: less hunger and less thinking about food between meals, slower gastric emptying so meals satisfy for longer and portions naturally shrink, and better blood-sugar handling, with insulin released only when needed and no hypo risk on its own.

Clinical evidence

In the pivotal STEP-1 trial, weekly 2.4 mg gave a mean 14.9% weight reduction over 68 weeks (2.4% on placebo), with about 69% losing at least 10%. The later STEP UP trial tested the higher 7.2 mg dose against 2.4 mg and placebo, all alongside a reduced-calorie diet and more activity.

Mean Weight Change at 72 Weeks (STEP UP) Bar chart, treatment-policy estimand: Wegovy 7.2 mg minus 18.7 percent, Wegovy 2.4 mg minus 15.6 percent, placebo minus 3.9 percent. Mean Weight Change at 72 Weeks 0 −5 −10 −15 −20 Percentage Change (%) −18.7 −15.6 −3.9 Wegovy 7.2 mg Wegovy 2.4 mg Placebo

STEP UP at 72 weeks, treatment-policy estimand (results regardless of whether participants stayed on treatment); on treatment, 7.2 mg reached 20.7%, with about one in three losing 25% or more. Side effects in STEP-1 (2.4 mg), mostly mild to moderate, peaking during escalation and easing over time: nausea 44.2% (17.4% on placebo), diarrhoea 31.5% (15.9%), vomiting 24.8% (6.6%), constipation 23.4% (9.5%). The 2.4 mg weight figure differs between trials (14.9% in STEP-1, 15.6% in STEP UP) as they are separate studies; averages, and individual results vary. Sources: Wilding JPH et al, NEJM 2021;384:989–1002; Novo Nordisk STEP UP, ADA 2025.

How semaglutide is prescribed

The injection starts low and steps up gradually to the lowest effective dose:

0.25 mg Initiation dose
0.5 mg Step-up
1 mg Step-up
1.7 mg Step-up
2.4 mg Maintenance dose
7.2 mg Higher maintenance dose

If a step doesn’t suit you, we hold or step back rather than push through. Some people reach their goal at 1 mg or 1.7 mg and stay there; others go on to 2.4 mg or 7.2 mg.

Wegovy (semaglutide) dose-escalation schedule. Five multi-dose FlexTouch pens, each holding four weekly doses: 0.25 mg for weeks 1 to 4 as the initiation dose, then stepping up through 0.5 mg (weeks 5 to 8), 1 mg (weeks 9 to 12) and 1.7 mg (weeks 13 to 16) to the 2.4 mg maintenance dose from week 17. A separate 7.2 mg single-dose pre-filled pen, supplied four pens per pack, is taken from week 21 onwards.
Wegovy® dose-escalation schedule. 0.25–2.4 mg come as FlexTouch® pens (four weekly doses each); 7.2 mg is a single-dose pen, four per pack. Your own plan is set with Mahyar.

Wegovy as a daily tablet (oral semaglutide)

Wegovy also comes as a once-daily tablet: the same active medicine, with its own dose ladder and way of being taken. It is one of two tablets we prescribe, alongside Foundayo (orforglipron), a different medicine. As a newly licensed medicine it carries the ▼ black triangle, so report any suspected side effects through the Yellow Card scheme.

Wegovy 1.5 mg tablets carton, semaglutide, oral use, 30 tablets. 1.5 mg
Wegovy 4 mg tablets carton, semaglutide, oral use, 30 tablets. 4 mg
Wegovy 9 mg tablets carton, semaglutide, oral use, 30 tablets. 9 mg
Wegovy 25 mg tablets carton, semaglutide, oral use, 30 tablets. 25 mg

The dose steps up about monthly as tolerated, agreed with Mahyar. Tablet milligrams differ from injection milligrams: the 25 mg tablet is broadly equivalent to the 2.4 mg injection, and nothing matches the 7.2 mg dose.

How the tablet is taken

  1. On an empty stomach, at least 8 hours after eating (for most, first thing in the morning).
  2. Swallow it whole with a small sip of water (up to about 120 mL). Do not split, crush or chew it.
  3. Wait 30 minutes before eating, drinking or other oral medicines; less than that reduces how much is absorbed.
  4. Once a day, every day. Miss a dose? Skip it and carry on the next day. No needles, no sharps bin, and the pack keeps at room temperature.

In its 64-week trial (OASIS 4) the tablet gave a mean 13.6% weight reduction (2.2% on placebo), with around 6 in 10 losing at least 10%: a separate trial, so not directly comparable with the injection figures above.

Side effects are almost identical to the injection: mostly digestive, nausea most often, usually mild and settling with time. The safety points below apply to both forms.

Ready to start or switch?

A direct switch runs from the 2.4 mg injection to the 25 mg Wegovy tablet, a week after your last injection. From a lower dose, or from Mounjaro or Foundayo, the move is planned individually. Supplied by collection or post.

Book a consultation

Key safety considerations

Common digestive side effects are covered above. The reactions to recognise quickly:

When to seek immediate medical attention

  • Pancreatitis. Severe, lasting pain in the upper abdomen, often spreading to the back, with or without vomiting. Stop semaglutide and seek immediate help; it must not be restarted if pancreatitis is confirmed.
  • Gallbladder events (gallstones, inflammation). Right upper-abdominal pain, fever, jaundice or persistent nausea. Seek prompt assessment.
  • Sudden vision changes. Sudden loss of vision or rapidly worsening eyesight is very rare, but contact a doctor urgently, as it can signal a serious eye condition (NAION).

Uncommon to rare, but act promptly if suspected. We brief every patient on these signs and report serious effects to the MHRA Yellow Card scheme.

Other points to discuss before or during treatment

  • Pregnancy and contraception. Not for use in pregnancy or breast-feeding. Use reliable contraception, and stop at least two months before trying to conceive.
  • Other medicines. Tell us if you take levothyroxine (thyroid levels may need checking) or warfarin or similar anticoagulants (clotting may need closer monitoring).
  • Staying hydrated. Sickness, vomiting or diarrhoea can cause dehydration, so keep fluids up, especially with kidney problems.

Authoritative information & resources

Discuss whether semaglutide is right for you

A real clinical conversation, not a tick-box form. £30 deposit, deducted from treatment cost.

Patient education

About the medicine

Foundayo® (orforglipron)

Orforglipron is a once-daily tablet licensed in the UK for weight management in adults. It is a different medicine from semaglutide and tirzepatide and, unlike the Wegovy tablet, can be taken at any time of day, with or without food. This is general information, not a substitute for the Patient Information Leaflet or a clinical consultation. Whether it suits you, and at what dose, is decided with Mahyar.

Generic name orforglipron
Brand & manufacturer Foundayo® · Eli Lilly
Drug class Non-peptide GLP-1 receptor agonist
Administration Once-daily tablet, any time of day

How it works

Orforglipron activates the GLP-1 receptor, the same target as semaglutide, but it is a small non-peptide molecule, which is why it works as an ordinary tablet. The result: less hunger, slower gastric emptying so meals satisfy for longer, and better blood-sugar handling, with insulin released only when glucose is high, so low blood sugar is uncommon on its own.

Clinical evidence: ATTAIN-1

The pivotal ATTAIN-1 trial followed 3,127 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes, on daily orforglipron or placebo for 72 weeks, alongside a healthy diet and physical activity.

Mean Weight Change at 72 Weeks (ATTAIN-1) Bar chart: orforglipron 5.5 mg minus 7.8 percent, 9 mg minus 9.3 percent, 17.2 mg minus 12.4 percent, placebo minus 0.9 percent. Mean Weight Change at 72 Weeks ORFORGLIPRON PLACEBO 0 −5 −10 −15 Percentage Change (%) −7.8 −9.3 −12.4 −0.9 5.5 mg 9 mg 17.2 mg Placebo

Trial averages at 72 weeks, alongside diet and activity changes; individual results vary substantially. At the highest dose, 77.1% of participants lost at least 5% of their body weight and 59.6% at least 10%, against 22.1% and 8.6% on placebo. The trial used capsules (6, 12 and 36 mg); the chart shows the equivalent tablet strengths, as capsule and tablet milligrams are not interchangeable. Source: Foundayo UK Summary of Product Characteristics, section 5.1 (ATTAIN-1).

These figures cannot be compared with the Mounjaro or Wegovy numbers above: they come from separate trials in different groups of people. Which medicine suits you is decided with Mahyar, from your history, your other medicines and how you respond.

How orforglipron is prescribed

Six tablet strengths, taken in order. Treatment starts low and steps up only as far as you need:

Foundayo 0.8 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 0.8 mg Starting dose
Foundayo 2.5 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 2.5 mg Step 2
Foundayo 5.5 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 5.5 mg Step 3
Foundayo 9 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 9 mg Step 4
Foundayo 14.5 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 14.5 mg Step 5
Foundayo 17.2 mg film-coated tablets carton, orforglipron, oral use, once daily, 30 tablets. 17.2 mg Maximum dose

You start on 0.8 mg and move to 2.5 mg after at least 30 days. Each further step waits at least 30 days and depends on your response and tolerability; if a step doesn’t suit you, we hold or step back rather than push through. Milligrams are not comparable with the injections or the Wegovy tablet. Prices are in Programme & Pricing above.

How the tablet is taken

  1. Once a day, at any time of day, with no food or water restrictions.
  2. Swallow it whole. Do not break, crush or chew it.
  3. Miss a dose? Take it as soon as you remember, but never more than one tablet in a day, even to make up a higher dose.
  4. No fridge needed. Keep the tablets in their original pack, protected from light.

Key safety considerations

Digestive side effects are the most common: nausea, constipation, diarrhoea, vomiting, indigestion and stomach pain. In the weight-management trials they affected 60.1% to 68.7% of people on orforglipron, against 36.3% on placebo, and led 3.7% to 6.8% to stop treatment, against 0.6%. They are usually mild to moderate, most frequent when starting and after each dose increase, and ease over time. Foundayo carries the ▼ black triangle, so report any suspected side effect through the Yellow Card scheme.

When to seek immediate medical attention

  • Pancreatitis. Severe pain in the stomach and back that does not go away. Stop orforglipron and seek immediate medical attention; it must not be restarted if pancreatitis is confirmed.
  • Serious allergic reaction. Breathing problems, swelling of the face or throat, wheezing, a fast heartbeat, pale cold skin, feeling dizzy or weak. Get immediate medical help.
  • Bowel obstruction or severe constipation. Severe tummy pain, a swollen tummy, vomiting, or being unable to pass wind or open your bowels.
  • Gallbladder problems. Pain in the upper tummy, fever, or yellowing of the skin or eyes. Seek prompt assessment.
  • Sudden vision changes or unusual visual symptoms. Contact a doctor urgently. Reported with GLP-1 medicines as a class, these can signal a serious eye condition (NAION).

Gallstones affect up to 1 in 10 people and pancreatitis up to 1 in 100; how often the others occur is not known. We brief every patient on these signs and report serious effects to the MHRA.

Other points to discuss before or during treatment

  • The contraceptive pill. Orforglipron can make it less effective. Switch to a non-oral method, or add a barrier method such as condoms, for 30 days after starting and for 30 days after every dose increase.
  • Pregnancy and breast-feeding. Not for use in either. Use effective contraception, and stop at least three weeks before trying to conceive.
  • Other medicines, including herbal ones. Some change orforglipron levels enough to limit the dose or rule it out, among them clarithromycin, itraconazole, ketoconazole, ritonavir, rifampicin, carbamazepine, phenytoin and St John’s wort. It also raises levels of simvastatin (the dose is halved) and rosuvastatin. Bring a full list of everything you take.
  • Diabetes and blood-pressure medicines. With insulin or a sulfonylurea, blood sugar can fall too low; with blood-pressure medicines, blood pressure can. Doses may need reducing.
  • Staying hydrated. Vomiting or diarrhoea can cause dehydration, which can affect the kidneys. Keep fluids up, especially with kidney problems.
  • Operations. Tell the team beforehand if you are having a general anaesthetic or deep sedation.

Authoritative information & resources

Discuss whether orforglipron is right for you

A real clinical conversation, not a tick-box form. £30 deposit, deducted from treatment cost.

Operational Standards

How we operate as a regulated UK pharmacy.

The operational systems, oversight, and accountability behind every consultation, prescription, and dispensed medicine.

All strengths held in stock.

All licensed strengths are kept at our Hampstead premises. Once your treatment is agreed, you can collect on the day, or have it posted on our next dispatch day for delivery before 1pm.

UK-licensed product only.

We dispense only medicines that hold a UK Marketing Authorisation, sourced through MHRA-approved supply chains. Each pen and tablet pack is traceable from manufacturer to dispensing.

Cold chain handling, end to end.

Injectable GLP-1 medicines require refrigeration. We dispense from temperature-monitored fridges, and postal orders ship in insulated packaging with ice packs via Royal Mail Special Delivery. The tablets are stored at room temperature, so no cold chain is needed.

GP and specialist liaison.

We strongly recommend GP notification and, as standard, send brief letters at key points in your treatment. Where you’re under specialist care (endocrinology, gynaecology, gastroenterology, bariatric), we coordinate with them too.

MHRA Yellow Card pharmacovigilance.

Significant adverse events seen in our patients are reported to the MHRA Yellow Card Scheme. Active pharmacovigilance is how UK medicine safety actually works, and it’s a duty we take seriously.

GPhC Registered Premises 1040582.

Hampstead Heath Pharmacy operates under General Pharmaceutical Council premises registration 1040582, with a named Superintendent Pharmacist (Mahyar Saremi) accountable for clinical governance.

Verify on the GPhC register

How it works

From booking to ongoing care, in five steps.

What to expect at each step, and what we’ll need from you. No surprises.

  1. Book your initial consultation.

    All bookings happen online, through our Semble portal. Choose FIRST Appointment (in person at our Hampstead clinic, or by secure video) and pay the £30 booking deposit to confirm your slot. The deposit is fully deducted from the cost of your treatment.

    • Online bookings only, no phone bookings or walk-ins
    • £30 deposit, deducted from your treatment cost
    • Same-day and next-day appointments often available
  2. Complete your intake questionnaire.

    Immediately after booking, you’ll receive an email with a link to your intake questionnaire. Complete it before your appointment. Mahyar reviews it ahead of time, so the consultation focuses on what matters to you, not on data entry.

    • For virtual consultations: upload photo ID (a GPhC requirement)
    • Switching providers: upload evidence of your most recent supply (e.g. a prescription label or dispensing receipt)
    • Reviewed by Mahyar before your appointment
  3. Attend your consultation with Mahyar.

    A real clinical conversation, not a tick-box form. Mahyar reviews your medical history, current medicines, weight history, and goals; discusses eligibility, expected benefits, and side-effect patterns; and decides together with you whether treatment is appropriate. If it isn’t, we’ll say so.

    • For first virtual consultations: weight verified on a scale (a GPhC requirement)
    • If treatment is appropriate, it’s prescribed and dispensed at the consultation
    • Honest assessment: we’d rather have a difficult conversation than process a deposit for the wrong programme
  4. Begin treatment.

    If treatment is right for you, you can leave with your first pen or tablet pack on the day from our Hampstead clinic, or have it posted on our next dispatch day (usually Monday or Thursday) by Royal Mail Special Delivery, Guaranteed by 1pm the next day. Mahyar walks you through injection technique, or exactly how to take the tablet, in person or during your video consultation.

    • Walk out with your medication on the day, or have it delivered with insulated cold-chain packaging
    • Pen needles (box of 100 4 mm, £5) and sharps bin (£2) available
    • Dedicated WhatsApp number for between-visit questions, with same-day or next-day replies during clinic hours
  5. Ongoing reviews and progress monitoring.

    Follow-up consultations are included with your medication at no separate consultation fee. At each review, Mahyar checks how the medication is actually working: body-composition changes, side-effect patterns, dose tolerability, and clinical response. Dose is escalated only when clinically appropriate and tolerated.

    • Follow-up consultations included, no separate fee
    • GP and specialist liaison letters at key points (with your consent)
    • Pause or stop at any time, with no cancellation penalty
Book your initial consultation

£30 deposit, deducted from treatment cost. No subscription or fixed contract.

Patient experiences

What our patients say.

Real Google reviews from three different patient journeys — in-person care, virtual consultations, and a switcher from another provider.

In-person care

After years of struggling with my weight, I’m so glad I found this clinic. Being treated in person by a specialist pharmacist prescriber, Mahyar Saremi, made all the difference. Having regular face-to-face reviews is miles better than using an online pharmacy — my plan was properly tailored, side effects were sorted quickly, and I felt completely safe. I’ve lost a substantial amount of weight sustainably and couldn’t be happier. Highly recommend!

Anita N.

Verified Google review

Virtual consultations

Wonderful service from the team at HH Pharmacy, and they are always on hand to ask for advice, etc. you pay more for guaranteed delivery but well worth it! Would highly recommend them, especially for weight loss medication!

Jackie W.

Verified Google review

Switched from online provider

I switched to Hampstead Heath Pharmacy for my weight loss injections after dealing with constant delays from a big provider, and it was such a good move. Mahyar gave me so much valuable advice that my previous provider completely missed. He’s always happy to answer my questions, which is incredibly reassuring. Having regular face-to-face reviews where they check my body composition and carefully sort out my dosage is brilliant. I’m steadily losing weight and finally feel properly looked after.

Behyar S.

Verified Google review

Find us

Medical weight loss in Hampstead, NW3, and across the UK by video.

We’re directly opposite Hampstead Heath Rail Station, ten minutes’ walk from Belsize Park, or online from wherever you are in the UK.

Hampstead Heath Pharmacy

Address
35 South End Road
Hampstead
London NW3 2PY
Areas we serve
Patients travel to us from across north west London, including Hampstead, Belsize Park, Swiss Cottage, West Hampstead, Primrose Hill, Camden, Gospel Oak and Kentish Town.
Nearest stations
  • Hampstead Heath Rail Station (Mildmay line): directly opposite
  • Belsize Park (Northern line): 10-minute walk
  • Hampstead (Northern line): 12-minute walk
Parking
Pay-and-display parking on South End Road and surrounding streets (within the Camden controlled parking zone).

Can’t make it to Hampstead?

Secure video consultations are available to patients across the United Kingdom, on Semble’s UK-approved consultation platform. The same Independent Prescriber, the same depth of clinical review, with no travel needed. Medication is dispatched to you with insulated cold-chain packaging by Royal Mail Special Delivery Guaranteed by 1pm.

Frequently asked questions

Answers to the questions patients ask most.

If your question isn’t covered here, ask Mahyar at your consultation, or email us at info@hhpharmacy.co.uk and we’ll do our best to help.

About our service

How is your service different from online weight-loss providers?

Three things: the same prescriber at every stage, a real clinical assessment, and a real pharmacy behind it. Mahyar, an Independent Prescriber, assesses you and makes every dose decision, and your medication comes from GPhC-registered premises in Hampstead that you can walk into.

  • Continuity of clinician. Online providers typically rotate prescribers, so you may see a different name on each renewal.
  • Real clinical assessment. Patients with complex histories (polypharmacy, hypothyroidism, PCOS, post-bariatric history) are properly assessed rather than excluded by an algorithm or a tick-box form.
  • Real pharmacy infrastructure. Genuine UK-licensed medication held in stock, with same-day in-store collection or temperature-controlled postal delivery. GPhC premises 1040582.

Is there a subscription or fixed contract?

No. There’s a £30 booking deposit (deducted from your treatment cost), and you pay only for the medication you use. There’s no monthly subscription, no automatic renewal, and no minimum commitment. We review with you regularly and you decide each time whether to continue.

What does it cost, and are there any hidden fees?

You pay for your medication and for any add-ons you need: postage for home delivery, pen needles and a sharps bin. The injections are priced per pen and the tablets per monthly pack, and every price is listed in Programme & Pricing. The £30 booking deposit is deducted from the cost of your treatment.

When treatment goes ahead there is no separate consultation charge, no escalation fee, no plateau review fee, and no subscription. If your assessment does not lead to a supply, a £30 consultation fee applies and your deposit covers it. Routine clinical support, including dose escalation, side-effect management, and GP or specialist liaison, is included in the cost of your medication while you remain on treatment.

Why do these medicines need regular reviews, especially in the first six months?

Because the dose changes. UK schedules build the dose up in monthly steps, so your first six months typically involve three to five separate dose decisions, depending on the medicine, and side effects cluster around each change.

GPhC guidance for prescribing at a distance also requires weight, height or BMI to be verified independently, not self-declared. We verify weight for every patient, with photo ID, in person or by video.

Our model is built around this: while your dose is changing, we supply one month of medicine at a time, and every supply comes with a review with the same prescriber. Once you are stable on your maintenance dose, we can supply more than one month at a time where that suits you and is clinically appropriate.

Eligibility & specific conditions

Can I take these medicines if I have hypothyroidism or another thyroid history?

Usually, yes. Stable hypothyroidism, including Hashimoto’s thyroiditis, is not a contraindication for any of the four medicines we prescribe: their UK licences list only allergy to the medicine or its ingredients. Some online providers exclude patients with any thyroid history as a blanket precaution, but the UK licences do not require this.

If your thyroid replacement (for example levothyroxine) is stable and your blood results are within target, we’ll assess your suitability as normal. The Wegovy tablet can increase the amount of levothyroxine you absorb, so its licence advises considering thyroid blood tests while you take both.

If you have a more complex thyroid history, including a personal or family history of medullary thyroid carcinoma, we’ll discuss the specifics with you before any prescribing decision.

Can I take these medicines while breastfeeding?

It depends on the medicine. The UK licence for Mounjaro says it could be considered during breastfeeding, so we assess this individually. Wegovy (injection or tablet) and Foundayo are not advised: their licences say they should not be used while breastfeeding.

For Mounjaro (tirzepatide), the Summary of Product Characteristics reports a study of 11 women in which the amount of tirzepatide in breast milk was undetectable to very low, and any small amount present is expected to be broken down in the infant’s digestive system rather than absorbed. It also notes that it is not known whether eating less on treatment affects the make-up of breast milk.

So if you are breastfeeding, Mounjaro is the only one of the four we would consider, and only after an individual assessment with Mahyar at your consultation.

What if I’m planning a pregnancy?

Stop before you try to conceive. The UK licences advise stopping Mounjaro at least one month before a planned pregnancy, Wegovy (injection or tablet) at least two months before, and Foundayo at least three weeks before. None of these medicines should be used during pregnancy.

If you become pregnant while on treatment, stop the medicine and tell us or your GP as soon as you can.

At your consultation we’ll discuss the right timing for your medicine and circumstances, and where helpful we can liaise with your GP or fertility specialist.

What about contraception while taking these medicines?

Use effective contraception while you are taking any of these medicines. If you rely on the contraceptive pill, two of them need extra care: Mounjaro and Foundayo may make the pill less reliable when you start and after each dose increase.

For Mounjaro, the licence advises adding a barrier method such as condoms, or switching to a non-oral method (implant, coil or injection), for four weeks after starting and four weeks after each dose increase. For Foundayo the advice is the same, for 30 days each time.

Wegovy, as an injection or a tablet, is not expected to make the pill less effective. With any of these medicines, vomiting or severe diarrhoea can stop the pill being absorbed, so follow your pill’s leaflet if that happens.

We go through this at your first consultation and at every dose increase.

Can I take these medicines alongside my current prescriptions?

In most cases, yes, but it depends on the combination, so please bring a complete list of your prescriptions and over-the-counter medicines to your first consultation. These medicines slow the emptying of the stomach, which can change how some tablets and capsules are absorbed.

Medicines that need careful dose control, such as warfarin, may need extra monitoring when you start or change dose. Nothing else should be swallowed for 30 minutes after the Wegovy tablet, and Foundayo interacts with several medicines, including some antibiotics, antifungals, HIV and epilepsy medicines, statins and St John’s wort.

Mahyar’s NHS background as a Lead Formulary Pharmacist means he assesses these combinations as a routine part of every consultation.

Side effects, eating & safety

What side effects should I expect, and how do you manage them?

The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea, indigestion, and reflux. They’re usually mild to moderate, peak during the dose-escalation phase, and decrease over time as your body adjusts.

How we manage them:

  • Slower dose escalation. If you’re struggling, we extend your time at the current dose rather than push you up a step.
  • Anti-nausea and reflux support. As an Independent Prescriber, Mahyar can prescribe supportive treatment alongside your weight-management medicine in the same consultation, without sending you elsewhere.
  • Constipation strategies. Hydration, fibre, and where appropriate, prescribed treatment.
  • Pause and resume. For severe or persistent side effects, a brief pause is sometimes the right answer.

Warning signs to know about: pancreatitis (severe, persistent pain in the upper abdomen, which needs immediate medical attention) and gallbladder problems, including gallstones (pain in the upper right abdomen, fever). The product information lists pancreatitis as uncommon (up to 1 in 100 people) and gallstones as common (up to 1 in 10). Both need prompt assessment if suspected, and every patient is briefed on these warning signs at consultation.

We report any serious adverse effects to the MHRA Yellow Card scheme as standard pharmacovigilance. You can also report a side effect yourself at yellowcard.mhra.gov.uk.

How do I get help if I have a question between appointments?

We provide a dedicated WhatsApp number for between-visit questions, with same-day or next-day replies during clinic hours. The number is shared with you at your initial consultation, and it gives you direct access to the team, not a chatbot or ticketing system.

It’s the fastest way to ask about side effects, dosing, scheduling, or anything else that doesn’t need a full consultation.

For urgent medical concerns or emergencies, such as severe abdominal pain (a possible sign of pancreatitis), signs of severe dehydration, or any other symptom needing immediate attention, please call 999 or NHS 111 directly. WhatsApp is for non-urgent questions only.

What should I eat or avoid while on treatment?

There is no special diet. These medicines work mainly by reducing your appetite, so the goal is eating well within a smaller appetite: prioritise protein, fibre and fluids, and go easy on large fatty meals, very sugary foods, alcohol and fizzy drinks.

Prioritise:

  • Protein at every meal, to help preserve muscle during weight loss, which we discuss at every review.
  • Vegetables, fruit, and whole grains for fibre and micronutrients.
  • Hydration. Nausea, vomiting or diarrhoea can leave you dehydrated, so drink water regularly through the day.

Reduce or avoid:

  • Large, high-fat meals, which worsen nausea and reflux because they sit in the stomach longer.
  • Very sugary foods and drinks, which add calories with little nutrition.
  • Alcohol, which worsens nausea, adds calories your appetite has no room for, and dehydrates.
  • Carbonated drinks for many patients, as they can amplify reflux and bloating.

Practical tips:

  • Eat smaller portions, more slowly, and stop when you feel full, not when the plate is empty.
  • Many patients find they prefer 4 to 5 small meals or snacks rather than 3 large meals.
  • If you struggle with nausea, plain dry foods (toast, crackers, rice) tend to be easiest when symptoms peak; avoid fatty, fried, or spicy foods at those times.

Within your programme, Danae Marshall, our Weight Management Clinic Coordinator and an APPI-certified Pilates instructor, can also give general guidance on the type of exercise that helps preserve muscle during weight loss, including for patients with injuries or physical limitations. More tailored dietary guidance can be discussed at consultation.

Do I need blood tests before starting?

Not always. Routine blood tests aren’t mandatory before starting, but they may be recommended based on your medical history, current medicines, and risk factors, which we’ll discuss at your consultation. If you would like them, we can take the sample here.

Our GLP-1 Weight Loss Monitoring Profile blood test can be done before starting treatment, or periodically (for example, annually) while on these medicines. It covers blood sugar, kidney, liver, cholesterol, thyroid and nutritional markers.

Outcomes & long-term plans

What if the medication doesn’t work for me?

We review it with you and, where appropriate, change the plan. We treat less than about 5% loss of your starting weight after an adequate trial as a non-response. At that point the options include adjusting the dose where there is room to, or switching to another licensed medicine.

The licences for both injections set a similar checkpoint: if you have not lost at least 5% by six months (for one of them, six months at your highest tolerated dose), a decision is needed on whether to continue.

Each medicine has its own licensed dose ladder, so a switch is planned individually with Mahyar, using how you responded to and tolerated the first. Some people respond well to one medicine after a poor response to another.

Can I stop the medication? Will I regain the weight?

Yes, you can stop at any time; there’s no fixed contract or lock-in. For most people, stopping is followed by some weight regain over the months that follow, so it is worth planning how you stop rather than simply running out.

In trials where people were switched to placebo after losing weight on treatment, weight rose steadily over the following year, although on average it stayed below where they had started. The amount varies with diet and exercise habits, individual metabolism, and how long you were on treatment. This isn’t a personal failure: these medicines act on appetite-regulating hormones, so when they stop, those effects wear off.

Many patients use these medicines as a long-term tool, sometimes at lower ‘maintenance’ doses, rather than a short-term intervention. Others taper off carefully with continued behavioural support. We’ll discuss your goals at the start so you have a clear picture of options before you commit.

Choosing your medicine: injections & tablets

How do I choose between the injections and the tablets?

We prescribe four licensed weight-loss medicines: two once-weekly injections, Mounjaro (tirzepatide) and Wegovy (semaglutide), and two once-daily tablets, Wegovy Oral (semaglutide) and Foundayo (orforglipron). The right one depends on your medical history, your other medicines, any previous treatment and the routine you can keep to, and is decided with Mahyar at your consultation.

The practical differences are simple. The injections are taken once a week and are kept in the fridge. The tablets are taken once a day, need no needles or sharps bin, and keep at room temperature, which many people find easier for work and travel. Between the tablets, Wegovy Oral is taken on an empty stomach with a 30-minute wait afterwards, while Foundayo has no food or water restrictions.

Prices for every strength are in Programme & Pricing. Switching between medicines later is possible where clinically appropriate, so your first choice is not a lock-in.

What’s the difference between the two tablets, Wegovy Oral and Foundayo?

They contain different active medicines and are not interchangeable. Wegovy Oral is semaglutide, the same active medicine as the Wegovy pen. Foundayo is orforglipron, a newer GLP-1 medicine licensed in the UK in August 2026, with the UK the first country in Europe to approve it. Each has its own dose ladder, so their milligram numbers are not comparable.

The everyday difference is how you take them. Wegovy Oral is taken on an empty stomach, swallowed whole with a sip of water, with nothing else to eat, drink or take for at least 30 minutes afterwards. Foundayo can be taken at any time of day, with no food or water restrictions, which suits people whose mornings don’t allow a fasting window. Both are one tablet a day, needle-free and kept at room temperature.

Because Wegovy Oral shares its active medicine with the Wegovy pen, there is a licensed route between the 2.4 mg injection and the 25 mg tablet. Foundayo sits on its own ladder, so moving onto it is planned individually.

Is Wegovy available as a tablet?

Yes. Wegovy Oral is a once-daily semaglutide tablet, licensed in the UK in June 2026. It contains the same active medicine as the once-weekly Wegovy injection and is taken as one tablet a day on an empty stomach. We prescribe all four strengths, with prices in Programme & Pricing.

You can book a consultation to start or switch, with your medication supplied by collection or by post. A second, different once-daily tablet, Foundayo (orforglipron), is also available; see the tablet comparison above.

What’s the difference between the Wegovy injection and the Wegovy tablet?

Both contain the same active medicine, semaglutide. The injection is given under the skin once a week. The tablet is taken once a day by mouth, on an empty stomach, swallowed whole with a sip of water, with nothing else to eat, drink or take for at least 30 minutes afterwards.

The two have different dose ladders, so the milligram numbers are not interchangeable between them. Because the tablet is taken by mouth, there are no needles, no sharps bin and no cold-chain delivery. Which form suits you is decided with Mahyar.

Can I switch from the Wegovy injection, or from Mounjaro, to a tablet?

Yes, where it is clinically appropriate. There is a licensed direct switch from the once-weekly 2.4 mg Wegovy injection to the 25 mg daily Wegovy tablet, started one week after your last injection. Any other move onto a tablet is planned individually with Mahyar.

If you are on a lower injection dose, or on a different medicine such as Mounjaro (tirzepatide), there is no fixed dose equivalence between them, so you usually start the tablet on its own dose ladder.

The same applies to Foundayo (orforglipron): it sits on its own dose ladder, with no fixed equivalence to any of the injections or to Wegovy Oral, so the move is planned using your dose history and how you have tolerated your current medicine.

Switching provider, your GP & supply

I’m switching from another provider: do I have to restart at the lowest dose?

In most cases, no. If you’re already established on a stable dose from another provider and tolerating it well, we will not automatically restart you at the starting dose. Mahyar reviews your prescribing history, current dose, side-effect record, and response to treatment, and continues from a clinically appropriate dose: your current dose or, where indicated for safety, one step down.

If you’re switching, please mention this on your intake questionnaire and upload evidence of your most recent supply from your current provider (for example, a prescription label or dispensing receipt). This protects you clinically: we need to confirm what dose you’ve actually been receiving before continuing it.

This is one of the most common reasons patients transfer to us. Some online providers automatically restart switching patients at the lowest dose for protocol reasons, which can be frustrating and is often clinically unnecessary.

Will you communicate with my GP and any specialists I see?

Yes, and we strongly recommend it. As standard, we send a brief letter to your GP after your initial consultation and at notable points in your treatment (dose changes, significant side-effect events, treatment completion). If you’re under the care of a specialist, such as an endocrinologist, gynaecologist, gastroenterologist or bariatric surgeon, we liaise with them too.

GP notification helps prevent gaps in your medical record, particularly around drug interactions and conditions that may not be visible to other providers. It is a meaningful safety measure that many online providers don’t offer.

You can opt out, but we strongly discourage this. Joined-up care is safer care, particularly if you have multiple conditions or take other medicines.

Is your medication genuine and UK-licensed? How is it kept cold during postal delivery?

Yes. All medication we supply is genuine and UK-licensed: Mounjaro and Foundayo (Eli Lilly), and Wegovy as pen or tablet (Novo Nordisk), sourced through authorised UK wholesale supply chains. We do not supply compounded GLP-1 medicines or unlicensed semaglutide products that some online sellers offer.

For patients who collect in person at our pharmacy in Hampstead, the pens go straight from our refrigerated storage into your hands, with no transit and no risk of temperature deviation.

For patients who choose postal delivery, pens are shipped in insulated packaging with ice packs by Royal Mail Special Delivery, Guaranteed by 1pm the next day. Orders go out on our usual dispatch days of Monday and Thursday, so your medication spends under 24 hours in transit, and our packaging is designed to hold the cold chain for that journey.

Tablet packs (Wegovy Oral and Foundayo) need no cold chain and travel safely at room temperature in the same next-day service.

Sources for the clinical answers. UK product information on emc: Mounjaro, Wegovy injection, Wegovy tablets and Foundayo. The weight-regain findings are the SURMOUNT-4 and STEP 4 trials, in section 5.1 of the Mounjaro and Wegovy documents.

Also the MHRA’s guidance for patients on GLP-1 medicines and the GPhC’s guidance on pharmacy services at a distance.

Book your consultation

Ready to start? Book your initial consultation.

In person at our Hampstead clinic, or by secure video. The same Independent Prescriber at every visit.

The initial consultation is a real clinical conversation, not a tick-box form. Mahyar will review your medical history, current medicines, and goals, discuss eligibility, and decide together with you whether starting treatment makes sense. If it doesn’t, we’ll say so.

  • Same Independent Prescriber every visit: Mahyar Saremi.
  • In-person at NW3, or by secure video. Your choice.
  • GP and specialist liaison included, with your consent.
  • GPhC Registered Premises 1040582, a regulated UK pharmacy.
About the £30 deposit: The deposit paid at the time of booking is not an extra fee. It will be fully deducted from the total cost of your treatment when you visit us, provided you adhere to our cancellation policy.

Before you book

  • Online bookings only. We don’t take bookings by phone or accept walk-ins for weight-management consultations.
  • Choose ‘FIRST Appointment’ for your initial visit with us, even if you’ve been on treatment elsewhere. Choose ‘FOLLOW UP’ only for review appointments after you’ve been seen by Mahyar before.
  • An intake questionnaire is emailed to you immediately after booking, and should be completed before your first appointment. If you’re switching providers, you’ll be asked to upload evidence of your most recent supply (e.g. a prescription label or dispensing receipt).
  • For first virtual consultations, you’ll need photo ID (uploaded via the questionnaire) and a scale for weight verification, both GPhC requirements for remote prescribing. The secure video link is sent in your booking confirmation, via Semble’s UK-approved platform.
  • GP notification is strongly recommended. It helps prevent gaps in your medical record and protects you clinically. You can opt out, but we strongly discourage it.
Can’t see the booking form? Open booking in a new tab
Medically reviewed

Mahyar Saremi

Superintendent Pharmacist & Specialist Independent Prescriber

GPhC Registration: 2069409 Last reviewed: Sep 2026 Next review due: May 2027